Abstract
Sirolimus-eluting stents (SESs; Cypher) have demonstrated a significant reduction in restenosis rates when compared to bare metal stents (BMSs). The purpose of this study was to evaluate the strategy of exclusive use of two SESs versus the combination of one BMS and one SES for two-vessel coronary artery disease (CAD). It was found that the selective use of one SES combined with one BMS in patients undergoing percutaneous coronary intervention that requires more than one stent is safe, feasible, and associated with favorable procedural, 30-day, and 6-month clinical outcomes when compared to the exclusive use of SESs.
Publication types
-
Comparative Study
-
Evaluation Study
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary
-
Blood Vessel Prosthesis Implantation
-
Coated Materials, Biocompatible / therapeutic use*
-
Combined Modality Therapy
-
Coronary Angiography
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / therapy*
-
District of Columbia
-
Female
-
Follow-Up Studies
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Male
-
Middle Aged
-
Postoperative Complications / diagnostic imaging
-
Postoperative Complications / etiology
-
Sirolimus / therapeutic use*
-
Stents*
-
Treatment Outcome
Substances
-
Coated Materials, Biocompatible
-
Immunosuppressive Agents
-
Sirolimus